Genmab A (GMAB) Cash & Equivalents (2018 - 2026)

Genmab A's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• Quarterly Cash & Equivalents fell 6.05% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 6.05% YoY) and the FY2025 annual result came in at $1.7 billion, up 24.28% from the prior year.
• Cash & Equivalents was $1.5 billion for Q1 2026 at Genmab A, down from $1.7 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $2.2 billion in Q4 2023 and bottomed at $1.3 billion in Q2 2025.
• A 4-year average of $1.6 billion and a median of $1.6 billion in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 37.39% — and 2025, when it advanced 24.28%.
• Genmab A's Cash & Equivalents stood at $2.2 billion in 2023, then sank by 37.39% to $1.4 billion in 2024, then grew by 24.28% to $1.7 billion in 2025, then dropped by 11.31% to $1.5 billion in 2026.
• Business Quant data shows GMAB's Cash & Equivalents at $1.5 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.8 billion in Q3 2025.